Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application

Zhu, Yuanchang; Xiao, Bufan; Zhang, Jingtao; Cui, Xinrun; Lu, Zheming; Wu, Nan

doi:10.3389/fonc.2021.763806

Cited by 7 publications

(6 citation statements)

References 76 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further enhance the longterm survival rate of patients with esophageal cancer, the implementation of neoadjuvant chemotherapy before surgery attracts extensive attention from medical staff and it shows good therapeutic effects (45). Multiple studies show that neoadjuvant chemotherapy can effectively improve the long-term survival rate of patients with esophageal cancer and alleviate patients' clinical symptoms (46,47). Nonetheless, neoadjuvant chemotherapy shows some limitations at present.…”

Section: Discussionmentioning

confidence: 99%

Systematic review and meta-analysis of endoscopic ultrasonography in staging diagnosis of esophageal cancer after neoadjuvant radiotherapy and chemotherapy

Li¹,

Wang²,

Kang³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Clinically, it is necessary to evaluate the overall situation of the tumor before treatment, understand the disease stage of the patient, and choose the most reasonable treatment plan. Therefore, it is necessary to seek an efficient and accurate staging diagnosis method. EUS is widely used in staging esophageal cancer, but its accuracy will be affected by the experience of endoscopic diagnosis physicians.

show abstract

Section: Discussionmentioning

confidence: 99%

Systematic review and meta-analysis of endoscopic ultrasonography in staging diagnosis of esophageal cancer after neoadjuvant radiotherapy and chemotherapy

Li¹,

Wang²,

Kang³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…A Prospective pilot study reported the benefit of anti-CD3-activated autologous αβT cell therapy in the treatment of ESCC ( 48 ). Furthermore, several clinical trials of CAR-T therapy for ESCC are ongoing, and the results may hopefully change the current treatment status of ESCC ( 49 ). Some clinical and basic research hotspots are characterized by emerging or declining hotspots in this field, such as meta-analysis, polymorphism, P53, and single nucleotide polymorphism.…”

Section: Discussionmentioning

confidence: 99%

Global research trend of esophageal squamous cell carcinoma from 2012 to 2022: a bibliometric analysis

Zhang

Leng²,

Fang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundEsophageal cancer is currently a worldwide health problem. Esophageal squamous cell carcinoma (ESCC) is the most common pathological type of esophageal cancer, and its treatment methods and therapeutic effects are relatively limited, so it also requires the unremitting efforts of basic and clinical researchers to overcome difficulties. Bibliometric analysis can help sort out global research trends and hotspots, but no bibliometric analysis of ESCC has been reported. Therefore, we performed this study to analyze the global trends and potential hotspots of ESCC to indicate future research directions.MethodsThe articles related to ESCC research were collected from the WoS Core Collection SCI-EXPANDED database from 2012 to 2022. The article information was analyzed by BiblioShiny and VOSviewer. Results were presented as bar and network visualization to describe the current trend of ESCC research. This was a retrospective study evaluating data that is publicly available online and at libraries and institutional review board approval, as such, was not demanded.ResultsThe global publication trend illustrated a strong growth in the ESCC research field (annual growth rate of 11.4%) and the citation trend increased from an average of 2.98 citations per article per year in 2012 to an average of 3.84 citations per article per year in 2019. With the corresponding author’s country, China contributed the largest number (5,063 articles). The scholars from China and USA had the most collaboration (427 times). China had the largest number of institutions conducting ESCC research. Oncotarget, Oncology Letters, and Annals of Surgical Oncology published the most articles, while Cancer Research, International Journal of Cancer, and Journal of Clinical Oncology had the most local citations. Furthermore, the clinical research hotspots involved in the treatment of ESCC and the basic research hotspots involved in tumor malignant phenotype have received the most attention in recent years.ConclusionOur study demonstrated that the research of ESCC has developed rapidly in recent years, and the academic institutions in China have played a decisive role in this field. The global research purpose is to find effective therapies against ESCC, so some emerging hotspots related to ESCC treatment, such as endoscopic therapy, chemoradiotherapy, immunotherapy, tumor microenvironment, and the epithelial-mesenchymal transition will receive more attention and develop rapidly in the future.

show abstract

“…Both viral and non-viral vectors have been used to genetically engineer CAR-NK cells ( 89 ). While the transduction efficiency of retroviral vectors is high, these vectors may cause insertional mutations, carcinogenesis, and other adverse effects ( 90 ). However, while lentiviral vectors have a low incidence of insertional mutations, their transfection efficiency in peripheral blood NK cells is as low as 20% ( 91 ).…”

Section: Combined Applications Of Car-nk Cells and Immune Checkpoint ...mentioning

confidence: 99%

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy

Yang

Zhao²,

Sun³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells is an attractive research field in tumor immunotherapy. While CAR is genetically engineered to express certain molecules, it retains the intrinsic ability to recognize tumor cells through its own receptors. Additionally, NK cells do not depend on T cell receptors for cytotoxic killing. CAR-NK cells exhibit some differences to CAR-T cells in terms of more precise killing, numerous cell sources, and increased effectiveness in solid tumors. However, some problems still exist with CAR-NK cell therapy, such as cytotoxicity, low transfection efficiency, and storage issues. Immune checkpoints inhibit immune cells from performing their normal killing function, and the clinical application of immune checkpoint inhibitors for cancer treatment has become a key therapeutic strategy. The application of CAR-T cells and immune checkpoint inhibitors is being evaluated in numerous ongoing basic research and clinical studies. Immune checkpoints may affect the function of CAR-NK cell therapy. In this review, we describe the combination of existing CAR-NK cell technology with immune checkpoint therapy and discuss the research of CAR-NK cell technology and future clinical treatments. We also summarize the progress of clinical trials of CAR-NK cells and immune checkpoint therapy.

show abstract

Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application

Cited by 7 publications

References 76 publications

Systematic review and meta-analysis of endoscopic ultrasonography in staging diagnosis of esophageal cancer after neoadjuvant radiotherapy and chemotherapy

Systematic review and meta-analysis of endoscopic ultrasonography in staging diagnosis of esophageal cancer after neoadjuvant radiotherapy and chemotherapy

Global research trend of esophageal squamous cell carcinoma from 2012 to 2022: a bibliometric analysis

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy

Contact Info

Product

Resources

About